Since its FDA approval in 2002, Atomoxetine (brand name Strattera) has become a second or third line option (after stimulants and sometimes after central alpha agonists) for ADHD in both children and adults. Does it work? Listen and find out!
We live in a new era, going online as much as possible for health care. My puppy and I shot this video during the 2020 National Foundation for Autism Research (virtual) Race for Autism to introduce you to the use of video for therapy and medical care. Enjoy!
https://www.facebook.com/NationalFoundationforAutismResearch/videos/208784277060666/
NFAR is doing so much to support families during this difficult time. They help teachers, care programs and do tech training for better jobs, while providing lots of resources to families. Please consider joining me in supporting NFAR by clicking the National Foundation for Autism Research link on the video page, maybe after you enjoy watching Charlie and me with our cartoons.
You Might Also Enjoy...
Since its FDA approval in 2002, Atomoxetine (brand name Strattera) has become a second or third line option (after stimulants and sometimes after central alpha agonists) for ADHD in both children and adults. Does it work? Listen and find out!
ADHD is one of the most treatable conditions in psychiatry if patients adhere to medication regimens. So, why are parents so resistant to stimulant medications and how can we approach these misconceptions?
Each year in the US, there are about 1.04 million divorces, affecting about 800,000 children. How can we navigate the complexities of treating a child with divorce?
Do antipsychotics have neurotoxic effects in youth? In this episode, we’ll be banging the drum of caution about antipsychotic use in children and adolescents.
With a growing body of evidence supporting its clinical efficacy and cost-effectiveness relative to traditional ABA approaches, the developmental model is being used with increasing prevalence across the US.
Prescribing Psychotropics bridges the gap between the complexities of drug pharmacokinetics and everyday clinical practice, providing clinicians more insight into how psychiatric drugs behave (or misbehave!) once their patients take them.